# Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation

> **NCT03850509** · PHASE2 · TERMINATED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** OPS-2071
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03850509
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-25
- **Primary completion:** 2020-05-22
- **Final completion:** 2020-05-22
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2021-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03850509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03850509, "Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03850509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*